

Table S 1. Subgroup analysis of TyG-BMI in CHB and CHB with newly diagnosed MASLD

Subgroup	Samples	Events	C_index	HR (95%CI)	P
treatment-naive	43	10	0.749	1.040(1.009,1.071)	0.010
treatment_experienced	88	31	0.650	1.020(1.004,1.036)	0.014
HBeAg_negative	85	28	0.657	1.026(1.008,1.044)	0.004
HBeAg_positive	46	13	0.711	1.026(1.003,1.050)	0.028
Low_HBV DNA levels	111	37	0.676	1.029(1.014,1.044)	<0.001
moderate-to-high HBV DNA levels	20	4	0.559	0.990(0.950,1.031)	0.628
Initial_HBeAg_negative	31	8	0.717	1.041(1.003,1.080)	0.033
Treated_HBeAg_positive	54	20	0.639	1.020(1.000,1.041)	0.056
Treated_HBeAg_positive	34	11	0.670	1.022(0.995,1.050)	0.106

Note: Data are presented as number of patients (n), event counts, C-index, hazard ratio (HR) with 95% confidence interval (CI), and P value. Subgroup abbreviations: Treatment_naive, patients without prior antiviral therapy; Treatment_experienced, patients receiving antiviral therapy; HBeAg_negative, hepatitis B e antigen negative; HBeAg_positive, hepatitis B e antigen positive; HBV DNA_low, HBV-DNA < 2000 IU/mL; HBV DNA_moderate-to-high, HBV DNA $\geq$ 2000 IU/mL; Initial_HBeAg_negative, treatment-naive patients with HBeAg negative; Treated_HBeAg_positive, treatment-experienced patients with HBeAg positive. C-index, concordance index; HR, hazard ratio; CI, confidence interval.




Figure S 1. Calibration Curves for Various Parameters




Figure S 2. DCA Curves for Each Indicator